DiscoveRx offers custom services

DiscoveRx Corp., which thus far has been known primarily for being the provider of the off-the-shelf HitHunter assays, has made things personal—or at least personalized—by launching custom labeling and profiling services.

Jeffrey Bouley
Register for free to listen to this article
Listen with Speechify
0:00
5:00
FREMONT, Calif.—DiscoveRx Corp., which thus far has been known primarily for being the provider of the off-the-shelf HitHunter assays, has made things personal—or at least personalized—by launching custom labeling and profiling services.
 
The new services—custom labeling has been under­way since spring and pro­filing is set to begin in late July or August—are focused on kinases and proteases. DiscoveRx considers this effort to be a "major step" in its goal of giving wider access to its technology platform, enzyme fragment comple­mentation, which forms the core of the HitHunter prod­ucts used in drug discovery and screening.
 
"We have been known for providing out-of-the-box assay kits and tools," notes Sailaja Kuchibhatla, senior VP, business development for DiscoveRx. "Now drug dis­covery researchers and oth­ers can make custom assays of their choice and specify what they want. They can screen kinases they might not have been able to before and they can enjoy more specific formats for protease substrates."
 
Services include labeling of biomolecules with their beta-galactosidase enzyme donor (ED) tag for unactive and active kinase screening as well as synthesizing protease substrates with ED tags to enable chemiluminescent assays for new protease targets.
 
"The drug discovery commu­nity has been requesting broader access to our tools and technology, and by providing them access to customized services, we will enable them to screen against a wider variety of kinase or protease tar­gets," says Dr. Pyare Khanna, CEO of DiscoveRx.
 
Of particular interest to drug discovery researchers should be kinase binding assays, which Kuchibhatla says allow screening against active or unactive kinases. "We see a lot of traction in the mar­ketplace from these assays."
 
"With unactive kinases being increasingly important in drug discovery, it is critical to have a technology that allows one to rapidly develop quality assays," Khanna adds. "This service allows one to consider earlier targets that were intractable due to technology limitations."

Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue